Back to Trial

Oracle Runs

Oracle findings and outcome history for A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis (NCT06380907).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 7:14 PM
Resolution Evidence
Outcome
NO
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Sponsor publicly said it discontinued this exact Phase 2 ZL-1102 psoriasis trial after reviewing interim data from the first 40 patients, following the independent Data and Safety Monitoring Board’s recommendation. That is a clearly negative trial-specific readout, not a positive one.

Sources
Sponsorir.zailaboratory.com5/8/25
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

Zai Lab said it decided to discontinue the global Phase 2 clinical trial of ZL-1102 after reviewing interim data from the first 40 enrolled participants and a recommendation from the independent Data and Safety Monitoring Board.

View source
Sponsorir.zailaboratory.com5/8/25
Form 10-Q for ZAI LAB LTD filed 05/08/2025

The company stated it decided to discontinue the global Phase II clinical trial of ZL-1102 following interim analysis from the first 40 participants and the board’s recommendation.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NOAccepted95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Sponsor publicly said it discontinued this exact Phase 2 ZL-1102 psoriasis trial after reviewing interim data from the first 40 patients, following the independent Data and Safety Monitoring Board’s recommendation. That is a clearly negative trial-specific readout, not a positive one.

Found Apr 1, 2026, 7:14 PMOutcome date May 8, 2025, 12:00 AMReviewed Apr 1, 2026, 7:16 PM
Sponsorir.zailaboratory.comMay 8, 2025, 12:00 AM
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
Zai Lab said it decided to discontinue the global Phase 2 clinical trial of ZL-1102 after reviewing interim data from the first 40 enrolled participants and a recommendation from the independent Data and Safety Monitoring Board.
Sponsorir.zailaboratory.comMay 8, 2025, 12:00 AM
Form 10-Q for ZAI LAB LTD filed 05/08/2025
The company stated it decided to discontinue the global Phase II clinical trial of ZL-1102 following interim analysis from the first 40 participants and the board’s recommendation.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:16 PM

Will the results be positive?

PendingtoNOcurrentNO
GPT-5.4 (OpenAI)95% confidenceReviewed Apr 1, 2026, 7:16 PM

Sponsor publicly said it discontinued this exact Phase 2 ZL-1102 psoriasis trial after reviewing interim data from the first 40 patients, following the independent Data and Safety Monitoring Board’s recommendation. That is a clearly negative trial-specific readout, not a positive one.